More than two years into the COVID-19 pandemic, people are realizing that the “new normal” will probably involve learning to co-exist with SARS-CoV-2. Some treatments are available, but with new variants emerging, researchers are looking toward new strategies. In ACS Infectious Diseases, scientists now report that apratoxin S4, an anticancer drug candidate that targets a human protein, can interfere with the replication of many viruses, including SARS-CoV-2 and influenza A, offering a possible pan-viral therapy.
UF startup and UF Innovate | Sid Martin Biotech graduate Oragenics, a biotech company dedicated to fighting infectious diseases including coronavirus, announces the publication of an article co-authored by Oragenics and collaborators at Inspirevax and the National Research Council of Canada (“NRC”) Human Health Therapeutics Research Centre in Scientific Reports, a Nature journal.
Multiple scientists from UF Scripps Biomedical Research will join a massive federal effort to develop antiviral drugs to treat the pandemic coronavirus and other viral threats.
A University of Florida study sheds new light on the reason people who recover from a bout of severe COVID-19 are still at increased risk for death in the year after their recovery. The culprit may be high levels of inflammation during the initial illness.
Oragenics, Inc. (“Oragenics” or the “Company”), a biotech company dedicated to fighting infectious diseases including coronavirus, announced that Kimberly Murphy, a member of the Company’s Board of Directors, will attend the upcoming World Vaccine Congress Washington that will be held on April 18-22 to showcase the Company’s lead product, NT-CoV2-1, an intranasal vaccine candidate, and to pursue business development opportunities.
UF startup and UF Innovate | Sid Martin Biotech graduate Oragenics, Inc. announced it has extended a licensing and collaboration agreement with the National Research Council of Canada (NRC) that enables Oragenics to pursue an intranasal vaccine designed to protect against future variants of coronaviruses.
Researchers at the University of Florida, have helped developed a COVID-19 testing device that can detect coronavirus infection in as little as 30 seconds as sensitively and accurately as a PCR, or polymerase chain reaction test, the gold standard of testing.
Oragenics, Inc., announced the initiation of a Good Laboratory Practice (GLP) toxicology study to evaluate the safety profile and immunogenicity of its NT-CoV2-1 vaccine
Oragenics, Inc. announced it has entered into an agreement with KBI Biopharma, Inc. for the process transfer, process optimization, and cGMP manufacturing of Oragenics’s intranasal vaccine candidate NT-CoV2-1, which is expressed in a proprietary CHO cell line.
Tests with lab animals show a vaccine given as a nasal spray produces high antibody volumes against SARS-CoV-2 infections and reduces viral loads. Results of tests by biotechnology companies Oragenics Inc., a Sid Martin Biotech alum located in Tampa, and Inspirevax in Laval, Quebec, with National Research Council of Canada, appear on the bioRxiv pre-publication server, and are not yet peer-reviewed.